• / Free eNewsletters & Magazine
  • / My Account
Home>Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

10/02/2017

Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides

  • PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018
  • In parallel, the Company advances its robust development programs for AsiDNA™ and belinostat, supported by recent promising combination data and preliminary clinical data expected in 2018
  • Company is well-financed into early 2020, with the resources to support the current clinical development plan

Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development of innovative drugs in oncology, in particular orphan cancers, today introduced its proprietary chemistry platform of decoy oligonucleotides, platON™.

PlatON™ is a proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. This platform and its potential applications are fully protected by a patent family encompassing notably US patent # 9,687,557 granted in June 2017.

Each of these three components is modifiable to generate various compounds expressing different properties and/or activities, with the common feature of targeting tumor DNA repair pathways through a decoy mechanism.

AsiDNA™, Onxeo’s first-in-class DNA break repair inhibitor, represents the first drug candidate generated from platON™. It has already undergone a convincing phase I clinical trial via intratumoral administration and demonstrated a very promising in-vivo efficacy profile via systemic administration.

The Company intends to leverage platON™ to expand its pipeline with additional innovative DNA-targeting drug candidates and expects to initiate the preclinical evaluation of a new drug candidate as soon as the first half of 2018.

We are very excited about the potential of platON™, a truly unique platform of decoy oligonucleotides,” said Françoise Bono, Chief Scientific Officer of Onxeo.As we continue to advance our two lead candidates, AsiDNA™ and oral belinostat, towards clinical development, platON™ will be generating new and unique compounds which will expand our pipeline in the highly sought-after field of DNA-targeting. We will apply our deep translational expertise, particularly in the field of oligonucleotides, to lead the preclinical and clinical development of these new compounds in the best possible way and demonstrate their potential in cancer treatment.”

©2017 Morningstar Advisor. All right reserved.